BearishMEDIUM severityEarnings7d ago

Spruce Biosciences GAAP EPS of -$8.51 misses by $2.83

Spruce Biosciences GAAP EPS of -$8.51 misses by $2.83 — $SPRB one-month chart
$SPRB daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOK’s read

Spruce Biosciences shares surged 5.99% to $49.34, near the lower end of its 52-week range, despite a GAAP EPS miss. Recent coverage has been overwhelmingly bearish, with most comments arriving in the last week, signaling concentrated pessimism. The Health Care sector shows calm today, but the stock’s recent price action suggests lingering investor interest.

Written by Wook AI Nov 9, 11:29 PM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about SPRB. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · spruce biosciencesEvent risk Low

Nothing reported about spruce biosciences across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 79% a year
Now $42.25Week $37.55–$46.95 (±11.1%)Month $32.62–$51.88 (±22.8%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: This one turns on a concrete figure ($8.51); set it against the recent trend before reading it as a turning point.
  • How the stock is trading: $SPRB -2.45% in the latest session.
  • Timing: It came out pre-market, so the next session was the first that could react.
Amount$8.51
Amount$2.83

Where the stock stands

Spruce Biosciences ($SPRB) fell 2.45% to $42.25 in the latest session. Over the past month it is up 4.6%. That leaves it 67% below its 52-week high of $127.90 and 11% above its low of $38.06, close to the bottom of its range. The year's high was 3.4 times its low, which makes double-digit swings fairly routine here.

What the filings say

In its latest report (10-Q, filed Nov 9, 2026), $SPRB lost $24.0M over the quarter to Sep 30, 2026. Operations used $44.6M of cash over the nine months to Sep 30, 2026 — about $5.0M a month — against $87.7M in cash on Sep 30, 2026. At that pace the cash covers about 18 months. It carried $7.8M of debt against $87.7M of cash on Sep 30, 2026 — net cash of $79.9M. The company filed an 8-K — the form for material events — on Nov 9, the same day as this story; it is $SPRB's own account and the first thing to read. Figures are as filed with the SEC; the $SPRB page has the full statements.

How much coverage it is getting

Wook has no other story on Spruce Biosciences from the last 30 days, so there is no recent run to compare this one with.

The bigger picture

With earnings, the number matters less than the number versus expectations — and guidance often matters more than both. A beat paired with a soft outlook can still get a cold reception. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.

What to watch next

The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $SPRB page, and they say what management has disclosed without a reporter in between. Where several outlets agree is usually the news; where they differ is the angle. Wook AI, at the top of the page, can work out how far $SPRB is from its high or compare this week's coverage with earlier weeks.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Seeking Alpha published this on November 9, 2026. $SPRB has moved +5.63% ($40.00 to $42.25). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy